Siemens Enters Dx Agreement with Pfizer
News Dec 16, 2013
Under the agreement, Siemens will be one of Pfizer's collaboration partners to develop and provide in vitro diagnostic tests for use in clinical studies and, potentially, eventual global commercialization with Pfizer products.
The partnership will leverage Siemens' worldwide leadership in providing clinical diagnostic solutions for hospital and reference laboratories, specialty laboratories and point-of-care settings (including clinics and physician offices) to help enable diagnostics development.
"Companion diagnostics are an important enabler of targeted therapies for patients," said John Hubbard, Senior Vice President and Worldwide Head of Development Operations at Pfizer. "This agreement with Siemens Healthcare Diagnostics is another example of Pfizer's commitment to develop new precision medicines to address unmet clinical needs."
Companion diagnostic tests are clinical tests linked to a specific drug or therapy intended to assist physicians in making more informed and personalized treatment decisions for their patients. When used in the drug development process, companion diagnostics may help pharmaceutical companies improve patient selection and treatment monitoring, determine the preferred therapy dosing for patients, and establish a protocol to help maximize the treatment benefit for patients.
"Our relationship with Pfizer marks a major milestone in Siemens' personalized medicine strategy," commented Dr. Trevor Hawkins, Senior Vice President, Strategy & Innovations, Diagnostics Division, Siemens Healthcare. "We look forward to collaborating with Pfizer to realize the goal of advancing innovative solutions that change the way patient care is delivered and, together, shape the future of diagnostic medicine."
The Siemens Clinical Laboratory (SCL), a "high-complexity," cutting-edge testing laboratory focused on advancing personalized medicine, will develop the companion diagnostic tests under the master agreement.
Researchers at the University of Arizona have completed the first-of-its-kind study that could aid in the treatment, diagnosis and prevention of cervical cancer by identifying cervicovaginal metabolic signatures, or "fingerprints" that distinguish patients with HPV, pre-cancerous cervical conditions and cancer.READ MORE